Share on StockTwits

Illumina (NASDAQ:ILMN) CEO Jay T. Flatley unloaded 30,000 shares of the stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $170.11, for a total transaction of $5,103,300.00. Following the completion of the sale, the chief executive officer now directly owns 381,262 shares of the company’s stock, valued at approximately $64,856,479. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Illumina (NASDAQ:ILMN) traded up 1.01% on Friday, hitting $172.70. 957,110 shares of the company’s stock traded hands. Illumina has a 52-week low of $72.13 and a 52-week high of $183.30. The stock has a 50-day moving average of $162.0 and a 200-day moving average of $146.9. The company has a market cap of $22.175 billion and a price-to-earnings ratio of 120.24. Illumina also was the recipient of a large drop in short interest during the month of June. As of June 13th, there was short interest totalling 10,265,824 shares, a drop of 41.3% from the May 30th total of 17,495,888 shares. Currently, 8.1% of the company’s shares are short sold. Based on an average trading volume of 2,518,211 shares, the short-interest ratio is presently 4.1 days.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.45 by $0.01. The company had revenue of $421.00 million for the quarter, compared to the consensus estimate of $391.50 million. During the same quarter last year, the company posted $0.46 earnings per share. Illumina’s revenue was up 27.2% compared to the same quarter last year. Analysts expect that Illumina will post $2.17 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Tuesday. They now have a $205.00 price target on the stock. Separately, analysts at Ned Davis Research upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Finally, analysts at Maxim Group upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. They now have a $205.00 price target on the stock. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Illumina presently has an average rating of “Buy” and a consensus price target of $146.71.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.